

Supplementary material 2. Summary of the excluded studies

Excluded references with reasons:

Wrong treatment comparison.

1. Actrn. Adding mitomycin C to Bacillus of Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial [Internet]. 2013 [cited 19th July 2019]. Available from: <http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364165>.
2. Allona Moncada A, García Vaquero S, Zuloaga Gómez A, Martínez Torres JL, López-Pardo R, Molina J, et al. Preliminary results of a multicenter study with mitomycin C in superficial bladder tumors (Ta, T1). *Actas Urol Esp* 1988;12:424-9.
3. Altay B, Girgin C, Kefi A, Cikili N. The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities? *Int Urol Nephrol* 2000;32:53-8.
4. Arends T, vander Heijden A, Witjes A. Results of a randomized controlled trial comparing intravesical combined chemohyperthermia with mitomycin-C versus BCG for adjuvant treatment of patients with intermediate and high risk non-muscle invasive bladder cancer. *J Urol* 2014;1:S45-6.
5. Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. *Eur Urol* 2016;69:1046-52.
6. Arends TJ, Nativ O, Maffezzini M, De Cobelli O, van der Heijden AG, Witjes JA. Results of the first randomized controlled trial comparing intravesical radiofrequency induced chemohyperthermia with mitomycin-C versus BCG for adjuvant treatment of patients with intermediate- and high-risk non-muscle invasive bladder cancer. *Eur Urol Suppl* 2015;14:e944.
7. Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. *Lancet Oncol* 2006;7:43-51.
8. Di Stasi SM, Giannantoni A, Giurioli A, Vespasiani G, Zampa G, Storti L, et al. Long-term follow-up of a randomised trial comparing sequential Bacillus Calmette-Guerin and electromotive mitomycin-C with Bacillus Calmette Guerin alone in high-risk superficial bladder cancer. *Eur Urol Suppl* 2006;5:191.
9. Di Stasi SM, Giannantoni A, Giurioli A, Vespasiani G, Zampa G, Storti L, et al. Sequential Bacillus Calmette-Guerin and electromotive mitomycin-C versus Bacillus Calmette-Guerin alone for high risk superficial bladder cancer: long-term follow-up results of a prospective controlled study. *J Urol* 2006;175:268.
10. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Zampa G, et al. Sequential Bacillus Calmette Guerin and electromotive mitomycin-C versus Bacillus Calmette Guerin alone for high-risk superficial bladder cancer: a prospective controlled study. *J Clin Oncol* 2004;22:391S.
11. Di Stasi SM, Giannantoni A, Stephen RL, Virgill G, Giurioli A, Storti L, et al. Sequential intravesical Bacillus Calmette Guerin and electromotive mitomycin-C for high risk superficial bladder cancer: a prospective controlled study. *J Urol* 2004;171:74.
12. Di Stasi SM, Riedl C, Giannantoni A, Verri C, Celestino F, De Carlo F, et al. Is intravesical BCG alone still the only truly effective intravesical therapy for non-muscle invasive bladder cancer? *J Urol* 2015;1:e381.
13. Di Stasi SM, Verri C, Liberati E, Masedu F, Topazio L, Valenti M. Intravesical sequential Bacillus Calmette-Guerin and electromotive mitomycin versus Bacillus Calmette-Guerin alone for stage PT1 urothelial bladder cancer. *J Urol* 2012;1:e674.
14. Di Stasi SM, Verri C, Liberati E, Masedu F, Valenti M. Intravesical sequential BCG and electromotive mitomycin versus BCG alone for stage pT1 urothelial bladder cancer. *Eur Urol* 2013;12:e698-9.
15. Di Stasi SM, Verri C, Liberati E, Zampa G, Masedu F, Valenti M. Intravesical sequential BCG and electromotive mitomycin versus BCG alone in high risk non-muscle invasive bladder cancer. *J Clin Oncol* 2012;30:15.
16. El Kader OA. Immediate mitomycin C instillation followed by usual BCG course versus usual BCG alone for superficial transitional cell carcinoma of the bladder (4 years experience). *J Urol* 2010;1:e567-8.
17. Euctr BE. A phase I/II multicentric Belgian prospective novel sequential chemo-immunotherapy regimen for adjuvant treatment in non-muscle invasive bladder cancer. Novel chemo-immunotherapy for non-muscle invasive bladder cancer [Internet]. 2011 [cited 2019 Jul 19]. Available from: <https://apps.who.int/trialsearch/Trial3.aspx?trialid=EUCTR2011-000607-41-BE>.
18. Euctr GB. A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of Bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance

Bacillus Calmette-Guerin therapy. Hyperthermia plus mitomycin (HYMN) [Internet]. 2010 [cited 2019 Jul 19]. Available from: www.clinicaltrialsregister.eu/ctr-search/trial/2008-005428-99/GB.

19. Gao CZ, Zhang JJ, Lu YL, Zhao HY. Instillation of BCG vaccine and mitomycin for the prevention of bladder neoplasms recurrence. *Chin J Cancer* 2002;6:644-5.
20. Gazzaniga P, Gradilone A, de Berardinis E, Sciarra A, Cristini C, Naso G, et al. A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer. *BJU Int* 2009;104:184-8.
21. Gelabert-Mas A. Six years of follow up. A prospective study on intravesical chemoprophylaxis with mitomycin-C and BCG alternating. Complete response rate and much lower tumor progression rate. *Br J Urol* 1997;80:34.
22. Gelabert-Mas A, Arango Toro O, Bielsa Gali O, Llado Carbonell C. A prospective and randomized study of the complete response, index of recurrences and progression in superficial bladder carcinoma treated with mitomycin C alone versus mitomycin C and BCG alternatively. *Arch Esp Urol* 1993;46:379-82.
23. Grossman HB. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. *Urol Oncol-Semin Ori* 2006;24:271-2.
24. Guerrero-Ramos F, Gonzalez-Padilla DA, Gonzalez-Diaz A, Duarte-Ojeda JM, Miranda-Utrera N, Villacampa-Auba F, et al., editors. BCG vs chemohyperthermia with mitomycin C for high-risk non-muscle invasive bladder carcinoma: preliminary results of hivec-hr randomized clinical trial. *J Urol*; 2019; 201:E620.
25. Hausladen DA, Wheeler MA, Altieri DC, Colberg JW, Weiss RM. Effect of intravesical treatment of transitional cell carcinoma with Bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. *J Urol* 2003;170:230-4.
26. Hayne D, Stockler M, Ives A, Houghton B, Braganza P, Chalasani V, et al. Sequential BCG and mitomycin intravesical therapy versus BCG alone for high-risk non-muscle invasive bladder cancer (NMIBC): pilot study and proposal for a 2-stage randomized phase III trial. *BJU Int* 2011;107:25-6.
27. Huang J, Wang GZ, Xu CI. Clinical trial of effect and adverse reaction of domestic therapeutic BCG for prevention of recurrence of superficial bladder cancer. *Chin J Biol* 2010;23:419-21.
28. Jarvinen R, Kaasinen E, Rintala E, Group T F. Re: long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and Bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up. *J Urol* 2013;190:2019.
29. Jarvinen R, Kaasinen E, Rintala E, Liukkonen T, Puolakka VM, Kallio J, et al. 15-year outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma (NMIBC) treated with 5 weekly mitomycin C (MMC) instillations followed by monthly Bacillus-Calmette Guerin (BCG) or alternating BCG and interferon-alpha2b (IFN) instillations. *Eur Urol* 2014;13:e1107.
30. Jauhiainen K, Rintala E. Superficial urinary bladder cancer. Results from the FinnBladder studies and a review on instillation treatments. *Ann Chir Gynaecol* 1993;206:31-8.
31. Kaasinen E, Rintala E, Pere AK, Kallio J, Puolakka VM, Liukkonen T, et al. Weekly mitomycin C followed by monthly Bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and Bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. *J Urol* 2000;164:47-52.
32. Kaasinen E, Wijkstrom H, Malmström PU, Hellsten S, Duchek M, Mestad O, et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. *Eur Urol* 2003;43:637-45.
33. Kelly J, Buckley L, Devall AJ, Loubiere LS, Barnwell JM, Mostafid H, et al. HYMN: a randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of BCG or institutional standard in patients with recurrence of non-muscle invasive bladder cancer (NMIBC) following induction or maintenance BCG therapy. *BJU Int* 2015;115:12.
34. Kirkali Z, Oosterlinck W, Sylvester R, Da Silva FC, Busch C, Algaba F, et al. Sequential chemo-immunotherapy with mitomycin C (MMC) and Bacillus Calmette-Guerin (BCG) versus BCG alone in patients with carcinoma in situ (CIS) of the urinary bladder. Results of EORTC GU group randomized phase II study 30993. *J Urol* 2010;1:568.
35. Kurth KH, Bouffieux C, Sylvester R, van der Meijden AP, Oosterlinck W, Brausi M. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. *Eur Urol* 2000;37 Suppl 3:1-9.
36. Lamm DL. Comparison of BCG with other intravesical agents. *J Urol* 1991;37:30-2.
37. Leblanc B, Duclos AJ, Bénard F, Côté J, Valiquette L, Paquin JM, et al. Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. *J Urol* 1999;162:1946-50.
38. Liberati E, Verri C, Topazio L, Valenti M, Di Stasi SM. Intravesical sequential BCG and electromotive mitomycin-C versus BCG alone for stage PT1 urothelial bladder cancer. *Anticancer Res* 2012;32:1861-2.

39. Matsumoto K, Kikuchi E, Shirakawa H, Hayakawa N, Tanaka N, Ninomiya A, et al. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guerin relapsing non-muscle-invasive bladder cancer. *BJU Int* 2012;110:E508-13.
40. NCT01094964. Hyperthermia and mitomycin C, Bacillus Calmette-Guerin, or standard therapy as second-line therapy in treating patients with recurrent bladder cancer [Internet]. 2010 [cited 2019 Jul 19]. Available from: <https://clinicaltrials.gov/ct2/show/NCT01094964>.
41. Nishimura K, Higashino M, Hara T, Oka T, Sugao H, Osafune M. Clinical study of intravesical instillation therapy for superficial bladder cancer. *J Urol* 1996;58:362-6.
42. Nohales TG, Cortadellas AR, Arango TO, Bielsa GO, Gelabert MA. Resultados de un estudio prospectivo de quimioprofilaxis con mitomicina-C y BCG alternadas: respuesta completa, Índice de recidivas y de progresión. *Arch Esp Urol* 1996;49:689-92.
43. Ooi Wei L, Stockler M, Hayne D. Re: Willem Oosterlinck, Ziya Kirkali, Richard Sylvester, et al. Sequential intravesical chemioimmunotherapy with mitomycin C and Bacillus Calmette-Guerin and with Bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC Genito-urinary Group Randomized Phase 2 Trial (30993). *Eur Urol* 2011;59:438-46. *Eur Urol* 2011;60: e2-3.
44. Peyromaure M, Zerbib M. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. *BJU Int* 2004;93:60-3.
45. Saxena S, Agrawal U, Agarwal A, Murthy NS, Mohanty NK. Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder. *BJU Int* 2006;98:1012-7.
46. Soloway MS. Follow up of patients receiving treatment for superficial bladder cancer with mitomycin C and BCG. *Prog Clin Biol Res* 1990;350:71-9.
47. Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Zampa G, et al. Sequential Bacillus Calmette Guérin and electromotive mitomycin-C versus Bacillus Calmette Guérin alone for high-risk superficial bladder cancer: a prospective controlled study. *Proc Annu Meet Am Assoc Cancer Res* 2004:390.
48. Steinberg RL, Brooks NA, Thomas LJ, Mott SL, O'Donnell MA. Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer. *Urol Oncol* 2017;35:201-7.
49. Svatek RS. Long-term outcomes of the FinnBladder-4 study. *Eur Urol* 2015;68:618-9.
50. Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and Bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. *J Urol* 1998;160:1668-71; discussion 71-2.
51. Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and Bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. *J Urol* 1999;160:1668-72.
52. Yabusaki N, Komatsu H, Tago K, Yamada Y, Ueno A. Intravesical instillation of Bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of Bacillus Calmette-Guerin. *Nippon Hinyokika Gakkai Zasshi* 1991;82:290-6.
53. Yari H, Fallahnezhad M, Haji KB, Tavasoli SS. Comparison of full-dose intravesical BCG versus half dose BCG and mitomycin-C in treatment of patients with superficial bladder cancer. *Eur Urol* 2010;9:595-6.

Wrong study design.

54. Ayres BE, Crew JP. Is immediate postoperative intravesical chemotherapy beneficial in non-muscle-invasive bladder cancer? *Br J Urol* 2010;105 Suppl:14-7.
55. Badalato GM, Hruby G, Razmjoo M, McKiernan JM. Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG? *Can J Urol* 2011;18:5890-5.
56. Bassi P, Iafrate M, Spinadin R, Carando R, Iannello R, Repele M, et al. Superficial bladder neoplasia unresponsive to endocavitary treatment: when should the treatment approach be changed? *Arch Ital Urol* 2001;73:181-6.
57. Boccafoschi C, Geraci E, Annoscia S, Montefiore F, Lozzi C, Leva G. Local immunoprophylaxis with BCG versus local chemoprophylaxis with doxorubicin or mitomycin C in the prevention of recurrence of superficial bladder cancer: comparative study. *Acta Urol Ital* 1991;5:149-52.
58. Braasch MR, Bohle A, O'Donnell MA. Risk-adapted use of intravesical immunotherapy. *BJU Int* 2008;102:1254-64.
59. Brausi M, Hurler R, Lembo A, Palladini PD. Immunotherapy with BCG in high risk recurrent bladder cancers previously treated with

- multiple cycles of chemotherapy: long-term results. *Acta Urol Ital* 1998;12:131-2.
60. Chen CH, Yang HJ, Shun CT, Huang CY, Huang KH, Yu HJ, et al. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer. *Urol Oncol* 2012;30:421-7.
 61. Chen HR, Kao CC, Tsao CW, Tang SH, En M, Cha TL, et al. Comparison of Different Treatment Schedules of Mitomycin C Intravesical Instillation in High-Risk Superficial Bladder Cancer Patients. *Aktuelle Urol* 2019;50:292-7.
 62. Cho IC, Kim EK, Joung JY, Seo HK, Chung J, Park WS, et al. Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea. *Anticancer Res* 2012;32:1493-8.
 63. de Jong Z, Pontonnier F, Plante P, Mansat A, Centa F. The course of 203 superficial urothelial malignant tumors of the bladder during conservative treatment. *Ann Urol (Paris)* 1989;23:269-74.
 64. de Vere White RW, Deitch AD, Daneshmand S, Blumenstein B, Lowe BA, Sagalowsky AI, et al. The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. A Southwest Oncology Group Study. *Eur Urol* 2000;37:595-600.
 65. Giannone E, Conti G. BCG vs mitomycin in patients affected by monocentric T1G2 bladder cancer: randomized study in diploid and aneuploid TCC. *Br J Urol* 1997;80:40.
 66. Gonzalez Padilla DA, Gonzalez Diaz A, Miranda-Utrera N, De La Rosa Kehrmann F, Villacampa-Auba F, Guerrero-Ramos F, editors. HIVEC HR: Chemohyperthermia with mitomycin C vs BCG for high-risk non-muscle invasive bladder cancer. Preliminary results from a randomized controlled trial. *Eur Urol* 2019;18: e768-70.
 67. Gulpinar O, Haliloluoglu AH, Gokce MI, Gogus C, Baltaci S. The value of perioperative mitomycin C instillation in improving subsequent Bacillus Calmette-Guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasive bladder cancer: a prospective randomized study. *International Braz J Urol* 2012;38:474-9.
 68. Iavarone C, Minocchi L, Arecchi S, Nicolucci D, Porcelli C, D'Orazi V, et al. A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder. *G Chir* 1996;17:289-91.
 69. Isrctn. HYMN: a trial comparing hyperthermia and mitomycin chemotherapy with a second BCG treatment, or other standard treatment, for bladder cancer that has come back [Internet]. 2009 [cited 2019 Jul 19]. Available from: www.isrctn.com/ISRCTN85785327.
 70. Jarvinen R, Kaasinen E, Rintala E, the FinnBladder Group. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and Bacillus Calmette-Guerin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up. *Scand J Urol Nephrol* 2012;46:411-7.
 71. Kaasinen E, Wijkstrom H, Malmström PU, Rintala E, Jahnsson S. 17 year follow-up of the Nordic CIS study: long-term results of 1 year BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. *Eur Urol* 2014;13:e1006.
 72. Lundholm C, Wester K, Busch C, Norlen BJ, Ekman P, Karlberg L, et al. 5-Year followup of a randomized prospective study comparing mitomycin C and Bacillus Calmette-Guerin in patients with superficial bladder carcinoma. *J Urol* 1999;161:1124-7.
 73. Malmström PU, Sylvester RJ. Rebuttal from authors re: Guido Dalbagni. Is intravesical Bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer? *Eur Urol* 2009;56:258-9.
 74. Matsumoto K, Kikuchi E, Horiguchi Y, Tanaka N, Miyajima A, Nakagawa K, et al. Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods. *J Urol* 2010;75:1385-90.
 75. Murillo I, Barja S. Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis [Internet]. 2019 [cited 2019 Jul 19]. Available from: <https://clinicaltrials.gov/ct2/show/NCT03982797>.
 76. NCT00023842. BCG with or without mitomycin in treating patients with bladder cancer [Internet]. 2003 [cited 2019 Jul 19]. Available from: <https://clinicaltrials.gov/ct2/show/NCT00023842>.
 77. NCT01442519. Sequential Bacillus Calmette-Guérin (BCG) and electromotive mitomycin-C versus Bacillus Calmette-Guérin (BCG) alone for high risk superficial bladder cancer [Internet]. 2011 [cited 2019 Jul 19]. Available from: <https://clinicaltrials.gov/ct2/show/NCT01442519>.
 78. Oosterlinck W, Kirkali Z, Sylvester R, Silva FC, Busch C, Algaba F, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and Bacillus Calmette-Guerin and with Bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). *Eur Urol* 2011;59:438-46.
 79. Oosterlinck W, Kirkali Z, Sylvester RJ, Calais Da Silva F, Busch C, Algaba F, et al. Sequential chemo-immunotherapy with mitomycin C (MMC) and Bacillus Calmette-Guerin (BCG) versus BCG alone in patients with carcinoma in situ (CIS) of the urinary bladder results of EORTC GU group randomized phase II study 30993. *Eur Urol* 2010;9:91.
 80. Rintala E. Results of a randomized phase III trial of sequential, intravesical therapy with mitomycin C and Bacillus Calmette-Guerin

versus mitomycin C alone in patients with superficial bladder cancer – comment. *J Urol* 1998;160:1671-2.

81. Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Alftan O. Alternating mitomycin C and Bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. FinnBladder Group. *J Urol* 1996;156:56-9; discussion 9.
82. Rintala E, Jauhiainen K, Rajala P, Ruutu M, Kaasinen E, Alftan O. Alternating mitomycin C and Bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The FinnBladder Group. *J Urol* 1995;154:2050-3.
83. Sekine H, Ohya K, Kojima S, Igarashi K, Fukui I. Equivalent efficacy of mitomycin C plus doxorubicin instillation to Bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder. *Int J Urol* 2001;8:483-6.
84. M, Court JB, Kynaston HG, Wilt TJ, Coles B, Mason M. WITHDRAWN: Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. *Cochrane Database Syst Rev* 2015;11:CD003231.
85. Smits G, Schaafsma E, Kiemeny L, Caris C, Debruyne F, Witjes JA. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. *J Urol* 1998;52:1009-13; discussion 13.
86. Sylvester RJ. Bacillus Calmette-Guerin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues. *Eur Urol* 2009;56:266-8; discussion 8.
87. van Gils-Gielen RJ, Witjes WP, Caris CT, Debruyne FM, Witjes JA, Oosterhof GO. Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. *J Urol* 1995;45:581-6.
88. Yang D, Li S, Wang H, Li X, Liu S, Han W, et al. Prevention of postoperative recurrence of bladder cancer: a clinical study. *Zhonghua Wai Ke za Zhi [Chin J Surg]* 1999;37:464-5.

Comment/letter.

89. Bismarck E, Schmitz-Dräger BJ. Adjuvant and neoadjuvant therapy of urinary bladder carcinoma. *Onkologie* 2004;10:S14-5.
90. Bochner BH. Intravesical Bacillus Calmette-Guerin combined with electromotive mitomycin for high-risk superficial bladder cancer. *Nat Clin Pract Oncol* 2006;3:474-5.
91. Bohle A. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose Bacillus Calmette-Guerin (27 mg) versus very low-dose Bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. *Int Braz J Urol* 2008;34:117-8.
92. Crawford ED. Randomized study of intravesical mitomycin-C, Bacillus-Calmette-Guerin, Tice and Bacillus-Calmette-Guerin, RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in-situ of bladder – comment. *J Urol* 1995;153:933.
93. Dalbagni G. Is intravesical Bacillus Calmette-Guerin better than mitomycin for intermediate-risk bladder cancer? *Eur Urol* 2009;56:257-8; discussion 8.
94. Han KS, You D, Jeong IG, Kwon T, Hong B, Hong JH, et al. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate. *J Korean Med Sci* 2015;30:252-8.
95. Kaasinen E, Rintala E, Hellstrom P, Viitanen J, Juusela H, Rajala P, et al. Factors explaining recurrence in patients undergoing chemoinmunotherapy regimens for frequently recurring superficial bladder carcinoma. *Eur Urol* 2002;42:167-74.
96. Morales A. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and Bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. *J Urol* 1999;161:1582-3.
97. Raviv G, Pinthus JH, Shefi S, Mor Y, Kaufman-Francis K, Levron J, et al. Effects of intravesical chemotherapy and immunotherapy on semen analysis. *J Urol* 2005;65:765-7.
98. Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP, Morales A. Re: results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and Bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer (multiple letters). *J Urol* 1999;161:1582-3.

Duplicate.

99. Jarvinen R, Marttila T, Kaasinen E, Rintala E, Aaltomaa S, Kallio J, et al. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly Bacillus Calmette-Guérin (BCG) or alternating BCG and interferon- α 2b instillations: prospective randomised FinnBladder-4 study. *Eur Urol* 2015;68:611-7.
100. Mondal HP, Yirang K, Mukhopadhyay C, Adhikary SS, Dutta B, Bhoj SS. Prospective randomized study between intravesical BCG and mitomycin-C for non-muscle-invasive urothelial carcinoma of urinary-bladder post TURBT. *Bangladesh J Med Sci* 2016;15:74-7.
101. Nouhaud FX, Rigaud J, Saint F, Colombel M, Irani J, Soulie M, et al. Final results of the phase III URO-BCG 4 multicenter study: ef-

- ficacy and tolerance of one-third dose BCG maintenance in nonmuscle invasive bladder cancer. *Anticancer Drugs* 2017;28:335-40.
102. Tong M, Yu LZ, Ding Y, Liu LB, Pan BN, Na YQ. Prevention of postoperative recurrence of human bladder carcinoma by intravesical instillation of immunotoxin, a clinical study. *Zhonghua Yi Xue za Zhi* 2003;83:201-3.
103. van der Meijden PM, Debruyne FM, Steerenberg PA, de Jong WH, Doesburg W. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands. *Prog Clin Biol Res* 1989;310:285-98.

No distinction of low- and mid-/high-risk participants.

104. NCT00384891. Hyperthermia treatment in conjunction with mitomycin C versus BCG for superficial bladder cancer [Internet]. 2006 [cited 2019 Jul 19]. Available from: <https://clinicaltrials.gov/ct2/show/NCT00384891>.
105. Wang FL, Qin WJ, Wang H, Dong QC, Liu HL, Zhang YT, et al. Efficacy of Brucea javanica oil, mitomycin and BCG for prophylaxis of recurrent superficial bladder cancer. *Chin J Cancer* 2010;17:622-4.
106. Wang SH. Intravesical BCG, mitomycin-C and thiotepa in the prevention of bladder tumor recurrence after operation. *Chin J Surg* 1992;30:410-2.

Wrong participant population.

107. Wang F, Qin W, Zhang G, Zhang Y, Liu H, Yang L, et al. Prospective clinical studies at the efficacy of Brucea javanica oil, mitomycin and BCG for preventing postoperative relapse of superficial bladder cancer through perfusion. *Chin-Ger J Clin Oncol* 2011;10:p228-31.